



## Dr Angelika Bickel

### Contact

Dr Angelika Bickel

T +41 71 494 9647

### Units

Medizinische Onkologie und Hämatologie

## Publications (2)

**Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. J Cancer Res Ther 2021; 17:276-278.**

**Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC cancer 2016; 16:656.**

## Projects (2)

**A phase II, open label, randomized, parallel arm study of**

*Clinical Studies - Oct 2, 2020 - Aug 29, 2021*

*Automatically Closed*

**MP0250; A phase I multi-centre, open-label, repeated-dose, dose-escalation study to assess safety, tolerability and pharmacokinetics of MP0250 in patients with advanced solid tumours**

*Clinical Studies - Oct 23, 2014 - Sep 30, 2016*

*Automatically Closed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)